RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Comparison of Cholinesterase Inhibitor Utilization Patterns and Associated Health Care Costs in Alzheimer’s Disease
Mark, T., Mucha, L., Want, S. S., Cuffel, B., McRae, T., & Del Valle, M. (2008). Comparison of Cholinesterase Inhibitor Utilization Patterns and Associated Health Care Costs in Alzheimer’s Disease. Journal of Managed Care Pharmacy, 22(1), 451-461. Article PMID: 18597574. https://doi.org/10.18553/jmcp.2008.14.5.451
Sustained treatment with a cholinesterase inhibitor (ChEI) is used in the management of the symptoms of Alzheimer's disease (AD). However, the characteristic declines in learning and memory seen in AD may erode the patient's ability to adhere to medication regimens with or without caregiver support.
